Livingstone acted as financial advisor to Steril Verona S.r.l. (“Steril Verona”), supporting the Company and its majority shareholders in the execution of a minority buyout leading to the exit of the minority shareholder, as well as in securing the financing required to support the Company’s next phase of industrial development.
Founded in 1997, Steril Verona is a family-owned company specializing in ethylene oxide (EO) sterilization for leading manufacturers of medical devices, healthcare instruments and pharmaceutical packaging. The Company operates three dedicated sterilization facilities in the province of Verona, covering a total surface area of approximately 31,000 sqm.
Livingstone supported the Company throughout the minority buyout process, assisted management in the preparation of the Business Plan underpinning the new growth strategy, and managed discussions and negotiations with the leading lending institutions selected to structure a financing package supporting both the transaction and the Company’s future growth.
“We are pleased to have once again supported the shareholders of Steril Verona in this new phase of development, building on a relationship that spans more than five years. This transaction further demonstrates the strength of our long-standing partnership and our ongoing commitment to supporting a dynamic and innovative company in its most important strategic decisions and growth initiatives,” said Umberto Rossi, Partner at Livingstone.
The transaction also highlights Livingstone’s ability to support companies operating in the Healthcare sector not only through M&A transactions, but also by providing high-value strategic financial advisory services.
